Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH, United States.
Clinical Trials Management Office, College of Medicine, The Ohio State University, Columbus, OH, United States.
Front Immunol. 2024 Aug 5;15:1397629. doi: 10.3389/fimmu.2024.1397629. eCollection 2024.
The acute respiratory distress syndrome (ARDS) is a common complication of severe COVID-19 and contributes to patient morbidity and mortality. ARDS is a heterogeneous syndrome caused by various insults, and results in acute hypoxemic respiratory failure. Patients with ARDS from COVID-19 may represent a subgroup of ARDS patients with distinct molecular profiles that drive disease outcomes. Here, we hypothesized that longitudinal transcriptomic analysis may identify distinct dynamic pathobiological pathways during COVID-19 ARDS.
We identified a patient cohort from an existing ICU biorepository and established three groups for comparison: 1) patients with COVID-19 ARDS that survived hospitalization (COVID survivors, n = 4), 2) patients with COVID-19 ARDS that did not survive hospitalization (COVID non-survivors, n = 5), and 3) patients with ARDS from other causes as a control group (ARDS controls, n = 4). RNA was isolated from peripheral blood mononuclear cells (PBMCs) at 4 time points (Days 1, 3, 7, and 10 following ICU admission) and analyzed by bulk RNA sequencing.
We first compared transcriptomes between groups at individual timepoints and observed significant heterogeneity in differentially expressed genes (DEGs). Next, we utilized the likelihood ratio test to identify genes that exhibit different patterns of change over time between the 3 groups and identified 341 DEGs across time, including hemoglobin subunit alpha 2 (), hemoglobin subunit beta (), von Willebrand factor C and EGF domains (), and carbonic anhydrase 1 (), which all demonstrated persistent upregulation in the COVID non-survivors compared to COVID survivors. Of the 341 DEGs, 314 demonstrated a similar pattern of persistent increased gene expression in COVID non-survivors compared to survivors, associated with canonical pathways of iron homeostasis signaling, erythrocyte interaction with oxygen and carbon dioxide, erythropoietin signaling, heme biosynthesis, metabolism of porphyrins, and iron uptake and transport.
These findings describe significant differences in gene regulation during patient ICU course between survivors and non-survivors of COVID-19 ARDS. We identified multiple pathways that suggest heme and red blood cell metabolism contribute to disease outcomes. This approach is generalizable to larger cohorts and supports an approach of longitudinal sampling in ARDS molecular profiling studies, which may identify novel targetable pathways of injury and resolution.
急性呼吸窘迫综合征(ARDS)是严重 COVID-19 的常见并发症,导致患者发病率和死亡率升高。ARDS 是一种由多种损伤引起的异质性综合征,导致急性低氧性呼吸衰竭。COVID-19 所致 ARDS 患者可能代表 ARDS 患者亚组,其具有不同的分子特征,从而影响疾病结局。在此,我们假设纵向转录组分析可能会识别 COVID-19 ARDS 期间的不同动态病理生物学途径。
我们从现有的 ICU 生物库中确定了一个患者队列,并建立了三个比较组:1)COVID-19 ARDS 住院存活患者(COVID 幸存者,n=4),2)COVID-19 ARDS 住院未存活患者(COVID 非幸存者,n=5),3)ARDS 其他病因对照组(ARDS 对照组,n=4)。在 ICU 入院后第 1、3、7 和 10 天,从外周血单核细胞(PBMCs)中分离 RNA,并进行批量 RNA 测序分析。
我们首先在单个时间点比较了各组的转录组,观察到差异表达基因(DEGs)存在显著异质性。接下来,我们利用似然比检验来识别在 3 组之间随时间变化呈现不同变化模式的基因,并鉴定出 341 个随时间变化的 DEGs,包括血红蛋白亚单位α 2()、血红蛋白亚单位β()、血管性血友病因子 C 和 EGF 结构域()和碳酸酐酶 1(),这些基因在 COVID 非幸存者中均表现出与 COVID 幸存者相比持续上调。在 341 个 DEGs 中,有 314 个在 COVID 非幸存者中与幸存者相比呈现出持续上调的相似基因表达模式,与铁稳态信号、红细胞与氧气和二氧化碳的相互作用、促红细胞生成素信号、血红素生物合成、卟啉代谢和铁摄取与转运的经典途径相关。
这些发现描述了 COVID-19 ARDS 幸存者和非幸存者 ICU 期间基因调控的显著差异。我们确定了多个表明血红素和红细胞代谢对疾病结局有影响的途径。这种方法适用于更大的队列,并支持 ARDS 分子谱研究中纵向采样的方法,这可能会识别出新的可靶向损伤和恢复途径。